NCT05304598

Brief Summary

Neonatal intubations are performed routinely in a NICU. Most intubations are still performed without the administration of medications (awake intubations). Some of the reasons are unavailability of a single good medication, the ease of administration, the physicians comfort level, side effects of medications including apnea, bradycardia, hypotension. Some units use a cocktail of different medications, each with their own side effects We are proposing to study the effects of a single medication, dexmedetomidine (precedex) for the purpose of sedation prior to intubation in neonates. This study will compare the efficacy of a single dose of dexmedetomidine to controls.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2022

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 14, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

March 14, 2022

Completed
17 days until next milestone

First Posted

Study publicly available on registry

March 31, 2022

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 20, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 20, 2024

Completed
Last Updated

March 28, 2025

Status Verified

March 1, 2025

Enrollment Period

2.4 years

First QC Date

March 14, 2022

Last Update Submit

March 25, 2025

Conditions

Keywords

sedationintubationneonatesdexmedetomidine

Outcome Measures

Primary Outcomes (1)

  • Oxygen Saturation Differences

    Compare oxygen saturation differences between the control and study group

    30 minutes

Study Arms (2)

Dexmedetomidine Group

ACTIVE COMPARATOR

a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes

Drug: Dexmedetomidine

Control Group

ACTIVE COMPARATOR

routine awake intubation as per current unit standard of care

Other: Usual Care

Interventions

a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes

Dexmedetomidine Group

routine awake intubation as per current unit standard of care,

Control Group

Eligibility Criteria

Age0 Days - 120 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • neonates
  • elective intubation
  • admitted to the NICU
  • Less than 44 weeks corrected gestational age requiring intubation

You may not qualify if:

  • babies requiring emergent intubation
  • Neonates with birth weight\<1250 grams and \<1 week of postnatal age
  • Neonates with major congenital malformations
  • Neonates with preexisting hypotension (MAP \< Gest Age)
  • Neonates with complex congenital heart disease and heart block

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maimonides Medical Center

Brooklyn, New York, 11219, United States

Location

MeSH Terms

Interventions

Dexmedetomidine

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Alok Bhutada

    Maimonides Medical Center

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 14, 2022

First Posted

March 31, 2022

Study Start

March 14, 2022

Primary Completion

August 20, 2024

Study Completion

August 20, 2024

Last Updated

March 28, 2025

Record last verified: 2025-03

Locations